Pharma R&D Outsourcing Market - Global Outlook & Forecast 2022-2027
Description
Pharma R&D Outsourcing Market - Global Outlook & Forecast 2022-2027
The global pharma R&D outsourcing market is expected to grow at a CAGR of 9.56% during 2022-2027.
MARKET INSIGHTS
In a world of exponentially growing information, increasingly sophisticated technology, and an unstable economic environment, pharmaceutical corporations are increasingly outsourcing research efforts to academia and private contract research organizations (CROs). The pharmaceutical R&D outsourcing market is expected to grow as pharmaceutical and biotechnology companies spend more on outsourced services. Outsourced R&D activities span basic research through late-stage development, including genetic engineering, target identification, target validation, assay creation, hit discovery and lead optimization (hit candidates-as-a-service), safety and efficacy assessments in animal studies, and human clinical trials.
MARKET DYNAMICS
Paradigm Shift Towards Virtual Clinical Trials
a) Allied Minds & Bristol-Myers Squibb
b) GSK & University of Leicester
c) Actelion Pharmaceuticals & Enamine
SEGMENTATION ANALYSIS
The pharma R&D outsourcing market is segmented on the product, stage of development, size of companies, therapy areas, and geography.
Insights by Product
Among all products, the small molecules segment reported a significant pharma R&D outsourcing market share. The small molecules segment is estimated to be higher because small molecules are likely to play a crucial part in easing the burden of chronic disease. This diverse group of small chemical compounds offers many benefits for scientists and researchers:
a) They have a wide-ranging use.
b) They are comparatively low in cost.
c) They allow for easy administration, including an oral route of administration.
d) They can pass within cell membranes to achieve their targets due to their small size.
e) They provide consistent results.
Pharmaceutical companies planning small molecule clinical studies need to work with the appropriate contract research organization (CRO) to conduct valuable research using reliable data. The food and Drug Administration (FDA) approved 50 novel drugs in 2021. 36 are small molecules which is 72% of the total approval of pharmaceutical drugs by the FDA.
Segmentation by Product Type
a) Among stages of development, the clinical segment reported a major share of around 64.13% in 2021. The clinical segment is estimated to be higher because, according to World Health Organization (WHO), approximately 47,689 clinical trials are in Phase I. The high number of clinical trials in phase 1 is highly outsourced. In outsourcing well-established data about patient recruitment, activities of clinical trials related to phase 1 and other procedures such as analysis and documentation are the easy thing done in the phase.
b) Phase 1 clinical trials required more than USD 30 million in capital investment. Compounds in oncology, respiratory diseases, and other therapeutic areas require a lot of money. Around 70% of drugs move from Phase I to the next phase states by US FDA.
c) Phase II can last for several years; as per the WHO, around 88,530 compounds in phase 2 clinical trials till 2022. As per US FDA, approximately 33% of new drugs are moved from phase II to the next.
d) The number of subjects usually ranges from hundreds to about 3,000. If the FDA agrees that the study results are positive, the FDA will approve the experimental drug or equipment. As per the WHO, around 68,999 drugs came to phase III till 2022. In this phase, doctors, physicians, or professionals do not know whether the treatment is better, so random participants are picked up to get the approval for new treatment and sent into the next phase. This procedure is often done in many places across the region/world at the same time to analyze the efficacy of drugs in different geography and demography.
Segmentation by Stage of Development
a) Among the size of the company, the small & mid-sized companies segment reported a major share of around 57.54% in 2021. The small & mid-sized companies market segment is estimated to be higher because, in 2019, the emerging therapeutic companies (ETC) were responsible for 73% (5,067 of 6,984) of global industrial, and pharmaceutical projects at all clinical stages, either alone or in collaboration with partners, with the rest being carried out by large companies.
b) SMEs will account for 71%, 76%, 68%, and 62% of Phase I, II, III, and new drug applications, respectively, compared to large companies. 45% of all clinical ETC pipeline projects are carried out in collaboration with other partners. Oncology is the main disease focus of these SME clinical projects.
c) In 2018, the Market researcher identified that 74 small pharmaceutical companies have total sales of $159 billion and 446 pharmaceuticals drugs in their R&D pipeline, 9 medium-sized companies with sales of $50 billion and 181 products, and sales of $139 billion in the R& D pipeline.
d) A 2017 BIO industry analysis shows that small biotechnology companies are responsible for 70% of all bio pharmacy clinical trials worldwide, representing 6,679 programs, 43% of which partner with other companies. It was carried out. Large companies conducted the remaining 30% of these clinical trials.
Segmentation by Company Size
a) Among therapy areas, the oncology segment reported a major share of around 30.71% in 2021. The oncology segments are estimated to be higher because there are 19.3 million new cancer instances and approximately 10 million fatalities worldwide in 2020, accounting for nearly one out of every six deaths as per Globocan 2020 report.
b) Oncology is one of the most dominant therapy areas for industry and non-industry-sponsored clinical trials. The rising prevalence of cancer conditions significantly contributed to oncology therapeutic area clinical trials. Changing the paradigm for testing cancer treatment in the world increased the global efforts toward generating evidence for oncology clinical trials.
c) In 2019 only around 30 FDA approvals were registered for chemotherapeutic drugs. In the US, about 361,628 clinical trials have been reported only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.
d) Global spending on anticancer medications climbed by 14.3% in 2020, reaching $164 billion. Spending is expected to reach $269 billion by 2025. The high prices of novel anticancer medicines drive much of this growth. The direct and indirect expenses of oncological treatments severely affect patients' treatment success and financial well-being worldwide.
e) In the US, around 361,628 clinical trials registered only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.
Segmentation by Therapy Area
The North America region reported a significant share of around 36.23% in 2021. The North America region is estimated to be higher because considerable investment by companies in R&D to strengthen the pipeline for chronic diseases is projected to boost the launch of novel therapeutics in North America. North America witnesses prominent start-up CROs working in the pharmaceutical R&D outsourcing market. The region also saw collaborations and partnerships among the pharmaceutical ecosystem's stakeholders.
Segmentation by Geography
o Canada
o UK
o France
o Italy
o Spain
o Japan
o India
o Australia
o South Korea
o Mexico
o Argentina
o Saudi Arabia
o Turkey
o UAE
VENDOR ANALYSIS
Vendors in the pharma R&D outsourcing market compete based on the wide range of services offered, quality, and scale-up development of pharmaceuticals. The market is so competitive that vendors aim to implement different strategies to maintain their competitive advantage over other vendors. The market players focus on acquisitions, partnerships, diversifying their outsourcing services, and strengthening their distribution networks to increase their market share. There are around 33 vendors in the pharmaceutical R&D outsourcing market, including key players and other prominent players.
Key Vendors
1. How big is the pharmaceutical R&D outsourcing market?
2. What is the growth rate of the global pharmaceutical R&D outsourcing market?
3. Who are the key players in the global pharma R&D outsourcing market?
4. Which geographical region leads in the pharma R&D outsourcing market?
5. What are the growth factors in the global pharmaceutical R&D outsourcing market?
The global pharma R&D outsourcing market is expected to grow at a CAGR of 9.56% during 2022-2027.
MARKET INSIGHTS
In a world of exponentially growing information, increasingly sophisticated technology, and an unstable economic environment, pharmaceutical corporations are increasingly outsourcing research efforts to academia and private contract research organizations (CROs). The pharmaceutical R&D outsourcing market is expected to grow as pharmaceutical and biotechnology companies spend more on outsourced services. Outsourced R&D activities span basic research through late-stage development, including genetic engineering, target identification, target validation, assay creation, hit discovery and lead optimization (hit candidates-as-a-service), safety and efficacy assessments in animal studies, and human clinical trials.
MARKET DYNAMICS
Paradigm Shift Towards Virtual Clinical Trials
- Virtual clinical trials or decentralized clinical trials can bring significant digital changes to clinical research methods and enhance the patient-centric ecosystem. These solutions include countless benefits such as technology, advanced applications, electronic devices, online social engagement platforms, artificial intelligence (AI), robotic process automation, and machine learning (ML).
- Patient recruitment is the most prominent cause of clinical delay, followed by significant patient absenteeism. Approximately 30% of phase 3 study discontinuances are said to be due to difficulty recruiting patients. These delays can cost pharmaceutical companies/sponsors up to USD 8 million daily. However, a complete digital or cross model of patient enrolment is employed in decentralized clinical trials. This helps reach the recruitment target easily and rapidly, making the entire process easy, and engaging.
- Artificial intelligence (AI) is used in numerous areas across the world. In healthcare, especially in the pharmaceutical industry, AI is making a notable change as it has varied uses in drug discovery & development, clinical trials, and pharmaceutical productivity. The life cycle of a new drug from a lab to a store is a chain of many complex events that take time and development. Such difficult circumstances can be minimized with the help of AI, and the target can be achieved in a short time.
- Many pharmaceutical companies implement innovative technologies such as AI and machine learning to achieve high-quality results in a short amount of time. In pharmaceutical product development, AI can manage the drug designing, decision making, and therapy determination for patients with personalized medicines; the generated clinical data can be stored for future drug development.
- Global key players from the pharma and biotech industry, such as Eli Lilly Amgen, Merck, LEO, AstraZeneca, Bayer, Novartis, J&J, and BASF, are now a part of machine learning for pharmaceutical discovery.
- New models are emerging, and the first innovation comes from the Clinical Research Organization (CRO). CROs establish early chemical / biological entry points for the disease, approach potential interested companies, and collaborate on integrated drug discovery projects that they have identified. Strategic partnerships have long been an essential feature of the pharmaceutical industry. Numerous in-licenses, out-licenses, joint research, and joint development agreements exist between biopharmaceutical companies and academic research institutes.
- In recent years, several significant outsourcing partnerships were done, such as the UK-based AstraZeneca partnering with academic organizations, the Cambridge University, focusing on drug development. It partnered with the University of Texas MD Anderson Cancer Center in the United States to develop immunotherapy.
a) Allied Minds & Bristol-Myers Squibb
b) GSK & University of Leicester
c) Actelion Pharmaceuticals & Enamine
SEGMENTATION ANALYSIS
The pharma R&D outsourcing market is segmented on the product, stage of development, size of companies, therapy areas, and geography.
Insights by Product
Among all products, the small molecules segment reported a significant pharma R&D outsourcing market share. The small molecules segment is estimated to be higher because small molecules are likely to play a crucial part in easing the burden of chronic disease. This diverse group of small chemical compounds offers many benefits for scientists and researchers:
a) They have a wide-ranging use.
b) They are comparatively low in cost.
c) They allow for easy administration, including an oral route of administration.
d) They can pass within cell membranes to achieve their targets due to their small size.
e) They provide consistent results.
Pharmaceutical companies planning small molecule clinical studies need to work with the appropriate contract research organization (CRO) to conduct valuable research using reliable data. The food and Drug Administration (FDA) approved 50 novel drugs in 2021. 36 are small molecules which is 72% of the total approval of pharmaceutical drugs by the FDA.
Segmentation by Product Type
- Small Molecules
- Biologics
a) Among stages of development, the clinical segment reported a major share of around 64.13% in 2021. The clinical segment is estimated to be higher because, according to World Health Organization (WHO), approximately 47,689 clinical trials are in Phase I. The high number of clinical trials in phase 1 is highly outsourced. In outsourcing well-established data about patient recruitment, activities of clinical trials related to phase 1 and other procedures such as analysis and documentation are the easy thing done in the phase.
b) Phase 1 clinical trials required more than USD 30 million in capital investment. Compounds in oncology, respiratory diseases, and other therapeutic areas require a lot of money. Around 70% of drugs move from Phase I to the next phase states by US FDA.
c) Phase II can last for several years; as per the WHO, around 88,530 compounds in phase 2 clinical trials till 2022. As per US FDA, approximately 33% of new drugs are moved from phase II to the next.
d) The number of subjects usually ranges from hundreds to about 3,000. If the FDA agrees that the study results are positive, the FDA will approve the experimental drug or equipment. As per the WHO, around 68,999 drugs came to phase III till 2022. In this phase, doctors, physicians, or professionals do not know whether the treatment is better, so random participants are picked up to get the approval for new treatment and sent into the next phase. This procedure is often done in many places across the region/world at the same time to analyze the efficacy of drugs in different geography and demography.
Segmentation by Stage of Development
- Clinical
- Non-Clinical
a) Among the size of the company, the small & mid-sized companies segment reported a major share of around 57.54% in 2021. The small & mid-sized companies market segment is estimated to be higher because, in 2019, the emerging therapeutic companies (ETC) were responsible for 73% (5,067 of 6,984) of global industrial, and pharmaceutical projects at all clinical stages, either alone or in collaboration with partners, with the rest being carried out by large companies.
b) SMEs will account for 71%, 76%, 68%, and 62% of Phase I, II, III, and new drug applications, respectively, compared to large companies. 45% of all clinical ETC pipeline projects are carried out in collaboration with other partners. Oncology is the main disease focus of these SME clinical projects.
c) In 2018, the Market researcher identified that 74 small pharmaceutical companies have total sales of $159 billion and 446 pharmaceuticals drugs in their R&D pipeline, 9 medium-sized companies with sales of $50 billion and 181 products, and sales of $139 billion in the R& D pipeline.
d) A 2017 BIO industry analysis shows that small biotechnology companies are responsible for 70% of all bio pharmacy clinical trials worldwide, representing 6,679 programs, 43% of which partner with other companies. It was carried out. Large companies conducted the remaining 30% of these clinical trials.
Segmentation by Company Size
- Small & Mid-Sized Companies
- Large Companies
a) Among therapy areas, the oncology segment reported a major share of around 30.71% in 2021. The oncology segments are estimated to be higher because there are 19.3 million new cancer instances and approximately 10 million fatalities worldwide in 2020, accounting for nearly one out of every six deaths as per Globocan 2020 report.
b) Oncology is one of the most dominant therapy areas for industry and non-industry-sponsored clinical trials. The rising prevalence of cancer conditions significantly contributed to oncology therapeutic area clinical trials. Changing the paradigm for testing cancer treatment in the world increased the global efforts toward generating evidence for oncology clinical trials.
c) In 2019 only around 30 FDA approvals were registered for chemotherapeutic drugs. In the US, about 361,628 clinical trials have been reported only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.
d) Global spending on anticancer medications climbed by 14.3% in 2020, reaching $164 billion. Spending is expected to reach $269 billion by 2025. The high prices of novel anticancer medicines drive much of this growth. The direct and indirect expenses of oncological treatments severely affect patients' treatment success and financial well-being worldwide.
e) In the US, around 361,628 clinical trials registered only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.
Segmentation by Therapy Area
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Musculoskeletal Disorders
- Central Nervous System Disorders
- Gastrointestinal Disorders
- Other Therapy Areas
The North America region reported a significant share of around 36.23% in 2021. The North America region is estimated to be higher because considerable investment by companies in R&D to strengthen the pipeline for chronic diseases is projected to boost the launch of novel therapeutics in North America. North America witnesses prominent start-up CROs working in the pharmaceutical R&D outsourcing market. The region also saw collaborations and partnerships among the pharmaceutical ecosystem's stakeholders.
Segmentation by Geography
- North America
o Canada
- Europe
o UK
o France
o Italy
o Spain
- APAC
o Japan
o India
o Australia
o South Korea
- Latin America
o Mexico
o Argentina
- Middle East & Africa
o Saudi Arabia
o Turkey
o UAE
VENDOR ANALYSIS
Vendors in the pharma R&D outsourcing market compete based on the wide range of services offered, quality, and scale-up development of pharmaceuticals. The market is so competitive that vendors aim to implement different strategies to maintain their competitive advantage over other vendors. The market players focus on acquisitions, partnerships, diversifying their outsourcing services, and strengthening their distribution networks to increase their market share. There are around 33 vendors in the pharmaceutical R&D outsourcing market, including key players and other prominent players.
Key Vendors
- Charles River Laboratories
- ICON
- IQVIA
- Labcorp Drug Development
- Medpace
- Parexel International Corporation
- Syneos Health
- Thermo Fisher Scientific
- Wuxi AppTec
- Lonza
- Boehringer Ingelheim
- Samsung Biologics
- AbbVie
- Advanced Clinical
- BioAnalytix
- Asymchem
- Alcami
- Bavarian Nordic
- Catalent
- Curia Global
- ChemPartner
- CMED
- Criterium
- Cromos Pharma
- Evotec
- Jubilant HollisterStier
- KBI Biopharma
- KCR S.A.
- Kemwell Biopharma
- Mesned Pharma Consult Center
- Midas Pharma
- Medelis
- Merck KGaA
- OCT Clinical
- Pharmaceutics International
- ProTrials Research
- PROMETRIKA
- QPS
- Singota Solutions
- Sofpromed
- Sanofi
- Taros chemicals
- Veristat
- Worldwide Clinical Trials
- WuXi Biologics
- Wacker Biotech B.V
1. How big is the pharmaceutical R&D outsourcing market?
2. What is the growth rate of the global pharmaceutical R&D outsourcing market?
3. Who are the key players in the global pharma R&D outsourcing market?
4. Which geographical region leads in the pharma R&D outsourcing market?
5. What are the growth factors in the global pharmaceutical R&D outsourcing market?
Table of Contents
357 Pages
- 1 RESEARCH METHODOLOGY
- 2 RESEARCH OBJECTIVES
- 3 RESEARCH PROCESS
- 4 SCOPE & COVERAGE
- 4.1 MARKET DEFINITION
- 4.1.1 INCLUSIONS
- 4.1.2 EXCLUSIONS
- 4.1.3 MARKET ESTIMATION CAVEATS
- 4.2 BASE YEAR
- 4.3 SCOPE OF THE STUDY
- 4.3.1 MARKET SEGMENTATION BY GEOGRAPHY
- 5 REPORT ASSUMPTIONS & CAVEATS
- 5.1 KEY CAVEATS
- 5.2 CURRENCY CONVERSION
- 5.3 MARKET DERIVATION
- 6 MARKET AT A GLANCE
- 7 INTRODUCTION
- 7.1 OVERVIEW
- 7.1.1 DRUG DEVELOPMENT
- 7.2 PHARMACEUTICALS AND THE NEED FOR OUTSOURCING R&D ACTIVITIES
- 7.2.1 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
- 8 PREMIUM INSIGHTS
- 8.1 MARKET OVERVIEW
- 8.1.1 PHARMACEUTICAL R&D OUTSOURCING MARKET SCENARIO
- 8.1.2 INSIGHT BY MARKET DYNAMICS
- 8.2 PHARMACEUTICAL R&D OUTSOURCING MARKET SEGMENTATIONS
- 8.2.1 INSIGHTS BY PRODUCT
- 8.2.2 INSIGHTS BY STAGE OF DEVELOPMENT
- 8.2.3 INSIGHTS BY COMPANY SIZE
- 8.2.4 INSIGHTS BY THERAPY AREA
- 8.2.5 INSIGHTS BY GEOGRAPHY
- 8.2.6 VENDOR LANDSCAPE
- 9 MARKET OPPORTUNITIES & TRENDS
- 9.1 PARADIGM SHIFT TOWARD VIRTUAL CLINICAL TRIALS
- 9.2 EMERGENCE OF AI IN DRUG DISCOVERY & DEVELOPMENT
- 9.3 RISING VENTURE CAPITALIST INVESTMENTS IN THE LIFE SCIENCES/BIOTECH INDUSTRY
- 9.4 SURGE IN USAGE OF CLOUD-BASED COMPUTING & RELATED SOFTWARE PLATFORMS IN R&D
- 10 MARKET GROWTH ENABLERS
- 10.1 INCREASING COLLABORATIONS AND PARTNERSHIPS AMONG CROS AND OTHER STAKEHOLDERS
- 10.2 INCREASING TARGET PATIENT DEMOGRAPHICS
- 10.3 SURGE IN OUTSOURCING OF CLINICAL TRIALS
- 11 MARKET RESTRAINTS
- 11.1 HIGH COST & LOW SUCCESS RATE OF PHARMACEUTICAL R&D
- 11.2 LACK OF TRANSPARENCY & SPECIFICITY, LONG TIMELINES, & CHANGING PRACTICES
- 11.3 GEOGRAPHICAL LOCATION AND CRUCIAL REGULATORY ASPECTS
- 12 MARKET LANDSCAPE
- 12.1 MARKET OVERVIEW
- 12.2 MARKET SIZE & FORECAST
- 12.2.1 INSIGHTS BY GEOGRAPHY
- 12.2.2 INSIGHTS BY STAGE OF DEVELOPMENT
- 12.2.3 INSIGHTS BY PRODUCT
- 12.2.4 INSIGHTS BY COMPANY SIZE
- 12.2.5 INSIGHTS BY THERAPY AREA
- 12.3 FIVE FORCES ANALYSIS
- 12.3.1 THREAT OF NEW ENTRANTS
- 12.3.2 BARGAINING POWER OF SUPPLIERS
- 12.3.3 BARGAINING POWER OF BUYERS
- 12.3.4 THREAT OF SUBSTITUTES
- 12.3.5 COMPETITIVE RIVALRY
- 13 STAGE OF DEVELOPMENT
- 13.1 MARKET SNAPSHOT & GROWTH ENGINE
- 13.2 MARKET OVERVIEW
- 13.3 CLINICAL
- 13.3.1 MARKET OVERVIEW
- 13.3.2 MARKET SIZE & FORECAST
- 13.3.3 MARKET BY GEOGRAPHY
- 13.4 NON-CLINICAL
- 13.4.1 MARKET OVERVIEW
- 13.4.2 MARKET SIZE & FORECAST
- 13.4.3 MARKET BY GEOGRAPHY
- 14 PRODUCT
- 14.1 MARKET SNAPSHOT & GROWTH ENGINE
- 14.2 MARKET OVERVIEW
- 14.3 SMALL MOLECULES
- 14.3.1 MARKET OVERVIEW
- 14.3.2 MARKET SIZE & FORECAST
- 14.3.3 MARKET BY GEOGRAPHY
- 14.4 BIOLOGICS
- 14.4.1 MARKET OVERVIEW
- 14.4.2 MARKET SIZE & FORECAST
- 14.4.3 MARKET BY GEOGRAPHY
- 15 COMPANY SIZE
- 15.1 MARKET SNAPSHOT & GROWTH ENGINE
- 15.2 MARKET OVERVIEW
- 15.3 SMALL & MID-SIZED COMPANIES
- 15.3.1 MARKET OVERVIEW
- 15.3.2 MARKET SIZE & FORECAST
- 15.3.3 MARKET BY GEOGRAPHY
- 15.4 LARGE COMPANIES
- 15.4.1 MARKET OVERVIEW
- 15.4.2 MARKET SIZE & FORECAST
- 15.4.3 MARKET BY GEOGRAPHY
- 16 THERAPY AREA
- 16.1 MARKET SNAPSHOT & GROWTH ENGINE
- 16.2 MARKET OVERVIEW
- 16.3 ONCOLOGY
- 16.3.1 MARKET OVERVIEW
- 16.3.2 MARKET SIZE & FORECAST
- 16.3.3 MARKET BY GEOGRAPHY
- 16.4 CARDIOVASCULAR DISEASES
- 16.4.1 MARKET OVERVIEW
- 16.4.2 MARKET SIZE & FORECAST
- 16.4.3 MARKET BY GEOGRAPHY
- 16.5 INFECTIOUS DISEASES
- 16.5.1 MARKET OVERVIEW
- 16.5.2 MARKET SIZE & FORECAST
- 16.5.3 MARKET BY GEOGRAPHY
- 16.6 MUSCULOSKELETAL DISORDERS
- 16.6.1 MARKET OVERVIEW
- 16.6.2 MARKET SIZE & FORECAST
- 16.6.3 MARKET BY GEOGRAPHY
- 16.7 CENTRAL NERVOUS SYSTEM DISORDERS
- 16.7.1 MARKET OVERVIEW
- 16.7.2 MARKET SIZE & FORECAST
- 16.7.3 MARKET BY GEOGRAPHY
- 16.8 GASTROINTESTINAL DISORDERS
- 16.8.1 MARKET OVERVIEW
- 16.8.2 MARKET SIZE & FORECAST
- 16.8.3 MARKET BY GEOGRAPHY
- 16.9 OTHER THERAPY AREAS
- 16.9.1 MARKET OVERVIEW
- 16.9.2 MARKET SIZE & FORECAST
- 16.9.3 MARKET BY GEOGRAPHY
- 17 GEOGRAPHY
- 17.1 MARKET SNAPSHOT & GROWTH ENGINE
- 17.2 GEOGRAPHIC OVERVIEW
- 18 NORTH AMERICA
- 18.1 MARKET OVERVIEW
- 18.2 MARKET SIZE & FORECAST
- 18.2.1 NORTH AMERICA: STAGE OF DEVELOPMENT
- 18.2.2 NORTH AMERICA: PRODUCT SEGMENTATION
- 18.2.3 NORTH AMERICA: COMPANY SIZE SEGMENTATION
- 18.2.4 NORTH AMERICA: THERAPY AREA SEGMENTATION
- 18.3 KEY COUNTRIES
- 18.3.1 US: MARKET SIZE & FORECAST
- 18.3.2 CANADA: MARKET SIZE & FORECAST
- 19 EUROPE
- 19.1 MARKET OVERVIEW
- 19.2 MARKET SIZE & FORECAST
- 19.2.1 EUROPE: STAGE OF DEVELOPMENT
- 19.2.2 EUROPE: PRODUCT SEGMENTATION
- 19.2.3 EUROPE: COMPANY SIZE SEGMENTATION
- 19.2.4 EUROPE: THERAPY AREA SEGMENTATION
- 19.3 KEY COUNTRIES
- 19.3.1 GERMANY: MARKET SIZE & FORECAST
- 19.3.2 UK: MARKET SIZE & FORECAST
- 19.3.3 FRANCE: MARKET SIZE & FORECAST
- 19.3.4 SPAIN: MARKET SIZE & FORECAST
- 19.3.5 ITALY: MARKET SIZE & FORECAST
- 20 APAC
- 20.1 MARKET OVERVIEW
- 20.2 MARKET SIZE & FORECAST
- 20.2.1 APAC: STAGE OF DEVELOPMENT
- 20.2.2 APAC: PRODUCT SEGMENTATION
- 20.2.3 APAC: COMPANY SIZE SEGMENTATION
- 20.2.4 APAC: THERAPY AREA SEGMENTATION
- 20.3 KEY COUNTRIES
- 20.3.1 CHINA: MARKET SIZE & FORECAST
- 20.3.2 JAPAN: MARKET SIZE & FORECAST
- 20.3.3 INDIA: MARKET SIZE & FORECAST
- 20.3.4 AUSTRALIA: MARKET SIZE & FORECAST
- 20.3.5 SOUTH KOREA: MARKET SIZE & FORECAST
- 21 LATIN AMERICA
- 21.1 MARKET OVERVIEW
- 21.2 MARKET SIZE & FORECAST
- 21.2.1 LATIN AMERICA: STAGE OF DEVELOPMENT
- 21.2.2 LATIN AMERICA: PRODUCT SEGMENTATION
- 21.2.3 LATIN AMERICA: COMPANY SIZE SEGMENTATION
- 21.2.4 LATIN AMERICA: THERAPY AREA SEGMENTATION
- 21.3 KEY COUNTRIES
- 21.3.1 BRAZIL: MARKET SIZE & FORECAST
- 21.3.2 MEXICO: MARKET SIZE & FORECAST
- 21.3.3 ARGENTINA: MARKET SIZE & FORECAST
- 22 MIDDLE EAST & AFRICA
- 22.1 MARKET OVERVIEW
- 22.2 MARKET SIZE & FORECAST
- 22.2.1 MIDDLE EAST & AFRICA: STAGE OF DEVELOPMENT
- 22.2.2 MIDDLE EAST & AFRICA: PRODUCT SEGMENTATION
- 22.2.3 MIDDLE EAST & AFRICA: COMPANY SIZE SEGMENTATION
- 22.2.4 MIDDLE EAST & AFRICA: THERAPY AREA SEGMENTATION
- 22.3 KEY COUNTRIES
- 22.3.1 TURKEY: MARKET SIZE & FORECAST
- 22.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
- 22.3.3 SOUTH AFRICA: MARKET SIZE & FORECAST
- 22.3.4 UAE: MARKET SIZE & FORECAST
- 23 COMPETITIVE LANDSCAPE
- 23.1 COMPETITION OVERVIEW
- 23.2 MARKET SHARE ANALYSIS
- 24 KEY COMPANY PROFILES
- 24.1 CHARLES RIVER LABORATORIES
- 24.1.1 BUSINESS OVERVIEW
- 24.1.2 CHARLES RIVER LABORATORIES IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.1.3 SERVICE OFFERINGS
- 24.1.4 KEY STRATEGIES
- 24.1.5 KEY STRENGTHS
- 24.1.6 KEY OPPORTUNITIES
- 24.2 ICON
- 24.2.1 BUSINESS OVERVIEW
- 24.2.2 ICON IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.2.3 SERVICE OFFERINGS
- 24.2.4 KEY STRATEGIES
- 24.2.5 KEY STRENGTHS
- 24.2.6 KEY OPPORTUNITIES
- 24.3 IQVIA
- 24.3.1 BUSINESS OVERVIEW
- 24.3.2 IQVIA IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.3.3 SERVICE OFFERINGS
- 24.3.4 KEY STRATEGIES
- 24.3.5 KEY STRENGTHS
- 24.3.6 KEY OPPORTUNITIES
- 24.4 LABCORP DRUG DEVELOPMENT
- 24.4.1 BUSINESS OVERVIEW
- 24.4.2 LABCORP DRUG DEVELOPMENT IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.4.3 SERVICE OFFERINGS
- 24.4.4 KEY STRATEGIES
- 24.4.5 KEY STRENGTHS
- 24.4.6 KEY OPPORTUNITIES
- 24.5 MEDPACE
- 24.5.1 BUSINESS OVERVIEW
- 24.5.2 MEDPACE IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.5.3 SERVICE OFFERINGS
- 24.5.4 KEY STRATEGIES
- 24.5.5 KEY STRENGTHS
- 24.5.6 KEY OPPORTUNITIES
- 24.6 PAREXEL INTERNATIONAL CORPORATION
- 24.6.1 BUSINESS OVERVIEW
- 24.6.2 PAREXEL INTERNATIONAL IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.6.3 SERVICE OFFERINGS
- 24.6.4 KEY STRATEGIES
- 24.6.5 KEY STRENGTHS
- 24.6.6 KEY OPPORTUNITIES
- 24.7 SYNEOS HEALTH
- 24.7.1 BUSINESS OVERVIEW
- 24.7.2 SYNEOS HEALTH IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.7.3 SERVICE OFFERINGS
- 24.7.4 KEY STRATEGIES
- 24.7.5 KEY STRENGTHS
- 24.7.6 KEY OPPORTUNITIES
- 24.8 THERMO FISHER SCIENTIFIC
- 24.8.1 BUSINESS OVERVIEW
- 24.8.2 THERMO FISHER SCIENTIFIC IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.8.3 SERVICE OFFERINGS
- 24.8.4 KEY STRATEGIES
- 24.8.5 KEY STRENGTHS
- 24.8.6 KEY OPPORTUNITIES
- 24.9 WUXI APPTEC
- 24.9.1 BUSINESS OVERVIEW
- 24.9.2 WUXI APPTEC IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.9.3 SERVICE OFFERINGS
- 24.9.4 KEY STRATEGIES
- 24.9.5 KEY STRENGTHS
- 24.9.6 KEY OPPORTUNITIES
- 24.10 LONZA
- 24.10.1 BUSINESS OVERVIEW
- 24.10.2 LONZA IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.10.3 SERVICE OFFERINGS
- 24.10.4 KEY STRATEGIES
- 24.10.5 KEY STRENGTHS
- 24.10.6 KEY OPPORTUNITIES
- 24.11 BOEHRINGER INGELHEIM
- 24.11.1 BUSINESS OVERVIEW
- 24.11.2 BOEHRINGER INGELHEIM IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.11.3 SERVICE OFFERINGS
- 24.11.4 KEY STRATEGIES
- 24.11.5 KEY STRENGTHS
- 24.11.6 KEY OPPORTUNITIES
- 24.12 SAMSUNG BIOLOGICS
- 24.12.1 BUSINESS OVERVIEW
- 24.12.2 SAMSUNG BIOLOGICS IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
- 24.12.3 SERVICE OFFERINGS
- 24.12.4 KEY STRATEGIES
- 24.12.5 KEY STRENGTHS
- 24.12.6 KEY OPPORTUNITIES
- 25 OTHER PROMINENT VENDORS
- 25.1 ABBVIE
- 25.1.1 BUSINESS OVERVIEW
- 25.1.2 SERVICE OFFERINGS
- 25.2 ADVANCED CLINICAL
- 25.2.1 BUSINESS OVERVIEW
- 25.2.2 PRODUCT OFFERINGS
- 25.3 BIOANALYTIX
- 25.3.1 BUSINESS OVERVIEW
- 25.3.2 PRODUCT OFFERINGS
- 25.4 ASYMCHEM
- 25.4.1 BUSINESS OVERVIEW
- 25.4.2 SERVICE OFFERINGS
- 25.5 ALCAMI
- 25.5.1 BUSINESS OVERVIEW
- 25.5.2 SERVICE OFFERINGS
- 25.6 BAVARIAN NORDIC
- 25.6.1 BUSINESS OVERVIEW
- 25.6.2 SERVICE OFFERINGS
- 25.7 CATALENT
- 25.7.1 BUSINESS OVERVIEW
- 25.7.2 SERVICE OFFERINGS
- 25.8 CURIA GLOBAL
- 25.8.1 BUSINESS OVERVIEW
- 25.8.2 SERVICE OFFERINGS
- 25.9 CHEMPARTNER
- 25.9.1 BUSINESS OVERVIEW
- 25.9.2 SERVICE OFFERINGS
- 25.10 CMED
- 25.10.1 BUSINESS OVERVIEW
- 25.10.2 PRODUCT OFFERINGS
- 25.11 CRITERIUM
- 25.11.1 BUSINESS OVERVIEW
- 25.11.2 PRODUCT OFFERINGS
- 25.12 CROMOS PHARMA
- 25.12.1 BUSINESS OVERVIEW
- 25.12.2 PRODUCT OFFERINGS
- 25.13 EVOTEC
- 25.13.1 BUSINESS OVERVIEW
- 25.13.2 SERVICE OFFERINGS
- 25.14 JUBILANT HOLLISTERSTIER
- 25.14.1 BUSINESS OVERVIEW
- 25.14.2 SERVICE OFFERINGS
- 25.15 KBI BIOPHARMA
- 25.15.1 BUSINESS OVERVIEW
- 25.15.2 SERVICE OFFERINGS
- 25.16 KCR S.A.
- 25.16.1 BUSINESS OVERVIEW
- 25.16.2 PRODUCT OFFERINGS
- 25.17 KEMWELL BIOPHARMA
- 25.17.1 BUSINESS OVERVIEW
- 25.17.2 SERVICE OFFERINGS
- 25.18 MESNED PHARMA CONSULT CENTER (MPCC)
- 25.18.1 BUSINESS OVERVIEW
- 25.18.2 SERVICE OFFERINGS
- 25.19 MIDAS PHARMA
- 25.19.1 BUSINESS OVERVIEW
- 25.19.2 SERVICE OFFERINGS
- 25.20 MEDELIS
- 25.20.1 BUSINESS OVERVIEW
- 25.20.2 PRODUCT OFFERINGS
- 25.21 MERCK KGAA
- 25.21.1 BUSINESS OVERVIEW
- 25.21.2 SERVICE OFFERINGS
- 25.22 OCT CLINICAL
- 25.22.1 BUSINESS OVERVIEW
- 25.22.2 PRODUCT OFFERINGS
- 25.23 PHARMACEUTICS INTERNATIONAL
- 25.23.1 BUSINESS OVERVIEW
- 25.23.2 SERVICE OFFERINGS
- 25.24 PROTRIALS RESEARCH
- 25.24.1 BUSINESS OVERVIEW
- 25.24.2 PRODUCT OFFERINGS
- 25.25 PROMETRIKA
- 25.25.1 BUSINESS OVERVIEW
- 25.25.2 PRODUCT OFFERINGS
- 25.26 QPS
- 25.26.1 BUSINESS OVERVIEW
- 25.26.2 PRODUCT OFFERINGS
- 25.27 SINGOTA SOLUTIONS
- 25.27.1 BUSINESS OVERVIEW
- 25.27.2 SERVICE OFFERINGS
- 25.28 SOFPROMED
- 25.28.1 BUSINESS OVERVIEW
- 25.28.2 SERVICE OFFERINGS
- 25.29 SANOFI
- 25.29.1 BUSINESS OVERVIEW
- 25.29.2 SERVICE OFFERINGS
- 25.30 TAROS CHEMICALS
- 25.30.1 BUSINESS OVERVIEW
- 25.30.2 SERVICE OFFERINGS
- 25.31 VERISTAT
- 25.31.1 BUSINESS OVERVIEW
- 25.31.2 PRODUCT OFFERINGS
- 25.32 WORLDWIDE CLINICAL TRIALS
- 25.32.1 BUSINESS OVERVIEW
- 25.32.2 PRODUCT OFFERINGS
- 25.33 WUXI BIOLOGICS
- 25.33.1 BUSINESS OVERVIEW
- 25.33.2 SERVICE OFFERINGS
- 25.34 WACKER BIOTECH B.V
- 25.34.1 BUSINESS OVERVIEW
- 25.34.2 SERVICE OFFERINGS
- 26 REPORT SUMMARY
- 26.1 KEY TAKEAWAYS
- 26.2 STRATEGIC RECOMMENDATIONS
- 27 QUANTITATIVE SUMMARY
- 27.1 MARKET BY STAGE OF DEVELOPMENT
- 27.1.1 NORTH AMERICA: STAGE OF DEVELOPMENT SEGMENTATION
- 27.1.2 EUROPE: STAGE OF DEVELOPMENT SEGMENTATION
- 27.1.3 APAC: STAGE OF DEVELOPMENT SEGMENTATION
- 27.1.4 LATIN AMERICA: STAGE OF DEVELOPMENT SEGMENTATION
- 27.1.5 MIDDLE EAST & AFRICA: STAGE OF DEVELOPMENT SEGMENTATION
- 27.2 MARKET BY PRODUCT
- 27.2.1 NORTH AMERICA: PRODUCT SEGMENTATION
- 27.2.2 EUROPE: PRODUCT SEGMENTATION
- 27.2.3 APAC: PRODUCT SEGMENTATION
- 27.2.4 LATIN AMERICA: PRODUCT SEGMENTATION
- 27.2.5 MIDDLE EAST & AFRICA: PRODUCT SEGMENTATION
- 27.3 MARKET BY COMPANY SIZE
- 27.3.1 NORTH AMERICA: COMPANY SIZE SEGMENTATION
- 27.3.2 EUROPE: COMPANY SIZE SEGMENTATION
- 27.3.3 APAC: COMPANY SIZE SEGMENTATION
- 27.3.4 LATIN AMERICA: COMPANY SIZE SEGMENTATION
- 27.3.5 MIDDLE EAST & AFRICA: COMPANY SIZE SEGMENTATION
- 27.4 MARKET BY THERAPY AREA
- 27.4.1 NORTH AMERICA: THERAPY AREA SEGMENTATION
- 27.4.2 EUROPE: THERAPY AREA SEGMENTATION
- 27.4.3 APAC: THERAPY AREA SEGMENTATION
- 27.4.4 LATIN AMERICA: THERAPY AREA SEGMENTATION
- 27.4.5 MIDDLE EAST & AFRICA: THERAPY AREA SEGMENTATION
- 27.5 MARKET BY GEOGRAPHY
- 27.5.1 CLINICAL: GEOGRAPHY SEGMENTATION
- 27.5.2 NON-CLINICAL: GEOGRAPHY SEGMENTATION
- 27.5.3 SMALL MOLECULES: GEOGRAPHY SEGMENTATION
- 27.5.4 BIOLOGICS: GEOGRAPHY SEGMENTATION
- 27.5.5 SMALL & MID-SIZED COMPANIES: GEOGRAPHY SEGMENTATION
- 27.5.6 LARGE COMPANIES: GEOGRAPHY SEGMENTATION
- 27.5.7 ONCOLOGY: GEOGRAPHY SEGMENTATION
- 27.5.8 CARDIOVASCULAR DISEASES: GEOGRAPHY SEGMENTATION
- 27.5.9 INFECTIOUS DISEASES: GEOGRAPHY SEGMENTATION
- 27.5.10 MUSCULOSKELETAL DISORDERS: GEOGRAPHY SEGMENTATION
- 27.5.11 CENTRAL NERVOUS SYSTEM DISORDERS: GEOGRAPHY SEGMENTATION
- 27.5.12 GASTROINTESTINAL DISORDERS: GEOGRAPHY SEGMENTATION
- 27.5.13 OTHER THERAPY AREAS: GEOGRAPHY SEGMENTATION
- 28 APPENDIX
- 28.1 ABBREVIATIONS
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
